As demonstrated in several vaccination models, and as observed by ourselves in previous experiments (data not shown), recombinant influenza vectors are not efficient inducers of heterospecific immune responses when used in single immunization or homologous vaccination protocols , , , ,  and . Therefore, we chose to test FLU-SAG2 as prime vector, to be administered in combination with a booster dose of Ad-SAG2. To this aim, BALB/c mice were primed intranasally
with vNA or FLU-SAG2. Four weeks later, they were boosted with an IN or a SC dose of Ad-Ctrl or Ad-SAG2. Serum samples were obtained 2 weeks after the prime and boost immunizations. Bronchoalveolar lavage (BAL) samples were obtained from animals sacrificed 2 weeks after boost immunization. Specific anti-SAG2 antibodies were detected by ELISA using a tachyzoite this website membrane extract enriched for GPI-anchored proteins (F3 antigenic fraction) . As shown in Fig. 4, when analyzing BAL samples, specific anti-SAG2 antibodies were detected only in animals that received prime and boost by IN route. It is noteworthy that this route of immunization elicited both IgG1 (Fig. 4B) and IgG2a (Fig. 4C) antibodies. Analysis of serum samples showed that significant levels of specific TGF beta inhibitor anti-SAG2 antibodies could be obtained by IN or SC vaccination (Fig. 5A). Overall, similar levels of IgG1 and IgG2a antibodies could be found in sera of immunized mice
(Fig. 5B and C). In all vaccination protocols, irrespective of the route of immunization, specific anti-SAG2 IgG antibodies were detected only after the boost immunization (Fig. 5A–C). In our previous experience with Ad-SAG2 and other recombinant adenoviruses, we observed that one immunization with these viruses were also unable to induce significant levels of antibodies against the recombinant antigens . Induction of anti-toxoplasma specific
CD4+ T and CD8+ T cells is considered to be the most important mechanism for protection against toxoplasmosis  and . It was demonstrated in different vaccination models that the efficacy of a particular protocol is directly related to its capacity to activate T cells in spleen  and . To evaluate whether the heterologous vaccination protocols are able to induce specific anti-SAG2 IFN-γ producing T cells at systemic level, tuclazepam spleen cells obtained 3 weeks after the boost immunization were stimulated in vitro with the F3 antigenic fraction of T. gondii in an IFN-γ ELISPOT assay. The results shown in Fig. 5D represent the average of two independent experiments. In mice primed and boosted by IN route, we were unable to detect specific IFN-γ producing T cells. In contrast, the number of antigen specific IFN-γ producing T cells was significantly higher in mice immunized with the combination of IN dose FLU-SAG2 and SC dose Ad-SAG2 recombinant viruses (207 ± 19) than in mice immunized with control viruses (38 ± 11).